Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | PDE4A | P27815 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19763310 | 1.00 | HIF1A (0.36) | HIF1AMAPTPDE4AKDR | |
| SCHEMBL15929702 | 0.87 | — | — | |
| SCHEMBL19102235 | 0.81 | — | — | |
| SCHEMBL19099007 | 0.81 | — | — | |
| SCHEMBL22236840 | 0.79 | — | — | |
| SCHEMBL18124124 | 0.79 | — | — | |
| SCHEMBL15929427 | 0.79 | — | — | |
| SCHEMBL25161936 | 0.75 | — | — | |
| SCHEMBL19372394 | 0.72 | — | — | |
| SCHEMBL490935 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 269 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122005879-A | Modified GRPR antagonist peptides for cancer imaging and treatment | 慕尼黑工业大学 | 2026-05-12 | — | — | CN | claimed |
| US-20260108637-A1 | USES OF PSMA-TARGETING AND TSPO-TARGETING COMPOUNDS FOR EVALUATION OF INJURIES IN THE PERIPHERAL NERVOUS SYSTEM | UNIV JOHNS HOPKINS (US) | 2026-04-23 | — | — | US | claimed |
| EP-4719494-A2 | USES OF PSMA-TARGETING AND TSPO-TARGETING COMPOUNDS FOR EVALUATION OF INJURIES IN THE PERIPHERAL NERVOUS SYSTEM | The Johns Hopkins University (US) | 2026-04-08 | — | — | EP | claimed |
| US-20250340701-A1 | DENDRIMER-DELIVERED ALPHA-PARTICLE RADIOTHERAPY FOR TREATMENT OF GLIOBLASTOMA AND OTHER CANCERS IN THE BRAIN | UNIV JOHNS HOPKINS (US) | 2025-11-06 | — | — | US | claimed |
| US-12447217-B2 | Fibroblast activation protein (FAP) inhibitors, FAP conjugates, and diagnostic and therapeutic uses thereof | NUCLIDIUM AG (CH) | 2025-10-21 | — | — | US | claimed |
| EP-4590345-A2 | HIGH-PURITY COPPER RADIOPHARMACEUTICAL COMPOSITIONS AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF | Nuclidium AG (CH) | 2025-07-30 | — | — | EP | claimed |
| EP-4590346-A1 | FIBROBLAST ACTIVATION PROTEIN (FAP) INHIBITORS, FAP CONJUGATES, AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF | Nuclidium AG (CH) | 2025-07-30 | — | — | EP | claimed |
| WO-2025151464-A1 | ALPHA-PARTICLE RADIONUCLIDE-ANTIBODY CONJUGATES FOR TREATMENT OF SOLID TUMORS | THE JOHNS HOPKINS UNIVERSITY (US) | 2025-07-17 | — | — | WO | claimed |
| WO-2025125621-A1 | CANCER-ASSOCIATED PROTEIN-TARGETED STRONG OR COVALENTLY BINDING PRECURSOR COMPOUNDS AND RADIOTRACERS | RADIOVAXX GMBH (DE) | 2025-06-19 | — | — | WO | claimed |
| CN-120022391-A | Tumor PD-L1 targeted radioactive diagnosis and treatment drug, and labeling precursor, preparation method and application thereof | 中国医学科学院药物研究所 | 2025-05-23 | — | — | CN | claimed |
| EP-3558395-A1 | TUMOR AND IMMUNE CELL IMAGING BASED ON PD-L1 EXPRESSION | The Johns Hopkins University (US) | 2019-10-30 | — | — | EP | claimed |
| US-20190314531-A1 | TUMOR AND IMMUNE CELL IMAGING BASED ON PD-L1 EXPRESSION | THE JOHNS HOPKINS UNIVERSITY | 2019-10-17 | — | — | US | claimed |
| WO-2018213537-A1 | REAGENT FOR SITE-SELECTIVE BIOCONJUGATION OF PROTEINS OR ANTIBODIES | RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (US) | 2018-11-22 | — | — | WO | claimed |
| WO-2018119313-A1 | TUMOR AND IMMUNE CELL IMAGING BASED ON PD-L1 EXPRESSION | THE JOHNS HOPKINS UNIVERSITY (US) | 2018-06-28 | — | — | WO | claimed |
| US-9447149-B2 | Methods and compositions for the rapid synthesis of radiometal-labeled probes | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2016-09-20 | — | — | US | claimed |
| US-20130108709-A1 | TREATMENT OF MITOCHONDRIA-RELATED DISEASES AND IMPROVEMENT OF AGE-RELATED METABOLIC DEFICITS | PROTEMIX CORPORATION LIMITED (NZ) | 2013-05-02 | — | — | US | claimed |
| US-20100160428-A1 | TREATMENT OF MITOCHONDRIA-RELATED DISEASES AND IMPROVEMENT OF AGE-RELATED METABOLIC DEFICITS | PROTEMIX CORPORATION LIMITED (NZ) | 2010-06-24 | — | — | US | claimed |
| EP-1948160-A1 | TREATMENT OF MITOCHONDRIA-RELATED DISEASES AND IMPROVEMENT OF AGE-RELATED METABOLIC DEFICITS | Protemix Corporation Limited (NZ) | 2008-07-30 | — | — | EP | claimed |
| WO-2007055598-A1 | TREATMENT OF MITOCHONDRIA-RELATED DISEASES AND IMPROVEMENT OF AGE-RELATED METABOLIC DEFICITS | PROTEMIX CORPORATION LIMITED (NZ) | 2007-05-18 | — | — | WO | claimed |
| WO-2006104396-A1 | PRE-COMPLEXED COPPER ANTAGONIST COMPOSITIONS | PROTEMIX CORPORATION LIMITED (NZ) | 2006-10-05 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160428-A1 | TREATMENT OF MITOCHONDRIA-RELATED DISEASES AND IMPROVEMENT OF AGE-RELATED METABOLIC DEFICITS | CS, GOT2, COX5B | HIF1A 994/4885MAPT 529/4885PDE4A 297/4885 |
| US-20130108709-A1 | TREATMENT OF MITOCHONDRIA-RELATED DISEASES AND IMPROVEMENT OF AGE-RELATED METABOLIC DEFICITS | TFAM, NDUFAB1, HSPA9 | HIF1A 517/4885MAPT 468/4885PDE4A 911/4885 |
| US-20250340701-A1 | DENDRIMER-DELIVERED ALPHA-PARTICLE RADIOTHERAPY FOR TREATMENT OF GLIOBLASTOMA AND OTHER CANCERS IN THE BRAIN | TUBA3E, TUBB2A, ADCYAP1R1 | HIF1A 2042/4885MAPT 443/4885PDE4A 1093/4885 |
| US-20260108637-A1 | USES OF PSMA-TARGETING AND TSPO-TARGETING COMPOUNDS FOR EVALUATION OF INJURIES IN THE PERIPHERAL NERVOUS SYSTEM | MUSK, TNNC1, TNNI3 | HIF1A 3186/4885MAPT 2225/4885PDE4A 1707/4885 |
| US-20190314531-A1 | TUMOR AND IMMUNE CELL IMAGING BASED ON PD-L1 EXPRESSION | CD274, PDCD1LG2, PDCD1 | HIF1A 322/4885MAPT 749/4885PDE4A 4124/4885 |
| US-12447217-B2 | Fibroblast activation protein (FAP) inhibitors, FAP conjugates, and diagnostic and therapeutic uses thereof | FAP, FIBP, FGFR1 | HIF1A 2486/4885MAPT 2117/4885PDE4A 752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.